Advanced Systemic Mastocytosis (AdvSM) — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Systemic mastocytosis is a diverse disorder marked by the accumulation of malignant mast cells in the bone marrow and various organs. The precise cause is not fully understood, although an activating mutation of the KIT gene, typically D816V, is evident in mast cells and occasionally in non-mast cell hematopoietic lineages. In advanced systemic mastocytosis (AdvSM), additional mutations in genes like TET2, SRSF2, ASXL1, RUNX1, JAK2, N/KRAS, CBL, and less frequently, EZH2, IDH2, ETV6, U2AF, or SF3B1, contribute to disease aggressiveness, especially in multi-mutated cases. Over 80% of systemic mastocytosis patients exhibit KIT mutations, most commonly KIT D816V. While many experience an indolent disease, a subset faces aggressive variants collectively termed “advanced systemic mastocytosis,” including aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, and mast cell leukemia. Advanced SM is a rare myeloid neoplasm characterized by uncontrolled mast cell accumulation, organ dysfunction, drug resistance, and poor prognosis. Around half of patients have an associated hematologic non-mast cell-lineage disease (SM-AHNMD) or develop one over time. Differential diagnoses exclude causes of cytopenias and abnormal JAK2 mutations, such as myelofibrosis, myelodysplasia, and other hematological malignancies, by detecting bone marrow infiltration by neoplastic mast cells with a KIT activation mutation. Advanced Systemic Mastocytosis (AdvSM) comprises three subtypes: aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). Survival in AdvSM is significantly shorter than the general population, with a median survival of 41 months for ASM, 24 months for SM-AHNMD, and 2 months for MCL.
- Aggressive systemic mastocytosis accounts for less than 10% of all SM cases, with a global prevalence estimated between 1/250,000–400,000.
Thelansis’s “Advanced Systemic Mastocytosis (AdvSM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced Systemic Mastocytosis (AdvSM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Advanced Systemic Mastocytosis (AdvSM) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Advanced Systemic Mastocytosis (AdvSM) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
